Patent ID: 11951172
Assignee: CRESCENDO BIOLOGICS LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 13:
14. An isolated binding agent comprising a first (VH) single domain antibody that binds to human LAG-3 and a second (VH) single domain antibody that binds to human LAG-3, wherein the first and/or second (VH) single domain antibody that binds to human LAG-3 comprises a CDR1 sequence as shown in SEQ ID NO: 1 or a CDR1 sequence as shown in SEQ ID NO: 1 comprising a Y to F substitution in CDR1 at position 32 of the sequence as shown in SEQ ID NO: 4, a CDR2 sequence as shown in SEQ ID NO: 2 or a CDR2 sequence as shown in SEQ ID NO: 2 comprising a N to S substitution in CDR2 at position 57 of the sequence as shown in SEQ ID NO: 4, a S to T substitution in CDR2 at position 58 of the sequence as shown in SEQ ID NO: 4, a N to I substitution in CDR2 at position 54 of the sequence as shown in SEQ ID NO: 4, a G to S substitution in CDR2 at position 55 of the sequence as shown in SEQ ID NO: 4, a G to D substitution in CDR2 at position 56 of the sequence as shown in SEQ ID NO: 4, a N to I substitution in CDR2 at position 57 of the sequence as shown in SEQ ID NO: 4, or a G to A substitution in CDR2 at position 59 of the sequence as shown in SEQ ID NO: 4, and a CDR3 sequence as shown from SEQ ID NO: 3 or a CDR3 sequence as shown in SEQ ID NO: 3 comprising a S to V substitution in CDR3 at position 106 of the sequence as shown in SEQ ID NO: 4, a S to A substitution in CDR3 at position 108 of the sequence as shown in SEQ ID NO: 4, or a A to T substitution in CDR3 at position 107 of the sequence as shown in SEQ ID NO: 4, or a CDR1 sequence as shown in SEQ ID NO: 5, a CDR2 sequence as shown in SEQ ID NO: 6, and a CDR3 sequence as shown in SEQ ID NO: 7.